Drug Search Results
More Filters [+]

Prednicarbate

Alternative Names: prednicarbate, dermatop, dermatop e emollient
Latest Update: 2018-01-16
Latest Update Note: Clinical Trial Update

Product Description

Prednicarbate is a synthetic nonhalogenated moderate to high potency corticosteroid. It is rapidly metabolised during skin permeation to prednisolone. Prednicarbate is indicated for relief of inflammation and pruritus associated with corticosteroid-responsive dermatological disorders such as dermatitis (eczema) [including atopic dermatitis] and psoriasis and can be used in children and elderly patients. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/18020557/)

Mechanisms of Action: GR Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Topical

FDA Designation: None *

Approval Status: Approved

Approved Countries: Brazil | Canada | Chile | Colombia | Croatia | Denmark | Dominican Republic | Ecuador | Egypt | Germany | India | Indonesia | Italy | Jordan | Korea | Lebanon | Mexico | Pakistan | Peru | Philippines | Slovenia | Spain | Sweden | Switzerland | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Prednicarbate

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title